WO2025030147 - EXTRACELLULAR VESICLES FOR INHIBITING INTERLEUKIN 6 (IL6 TRANS-SIGNALING AND VASCULAR EPIDERMAL GROWTH FACTOR (VEGF)-SIGNALING
National phase entry is expected:
Publication Number
WO/2025/030147
Publication Date
06.02.2025
International Application No.
PCT/US2024/040820
International Filing Date
02.08.2024
Title **
[English]
EXTRACELLULAR VESICLES FOR INHIBITING INTERLEUKIN 6 (IL6 TRANS-SIGNALING AND VASCULAR EPIDERMAL GROWTH FACTOR (VEGF)-SIGNALING
[French]
VÉSICULES EXTRACELLULAIRES POUR INHIBER LA SIGNALISATION DE L'INTERLEUKINE 6 (IL6) TRANS ET LA SIGNALISATION DU FACTEUR DE CROISSANCE VASCULAIRE ENDOTHÉLIALE (VEGF)
Applicants **
MANTRA BIO, INC.
Inventors
HALENBECK, Rob
CARR, Andrew
FUENTES, Maria, E.
GOSLING, Jennifa
GOTTLIEB, Colin
MOK, Alex
Priority Data
63/530,467
02.08.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5934 | |
| EPO | Filing, Examination, Granting | 120476 | |
| Japan | Filing, Examination, Granting | 4884 | |
| South Korea | Filing, Examination, Granting | 8924 | |
| USA | Filing, Examination, Granting | 29810 |
Total:
170,028
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are engineered extracellular vesicles for inhibiting 1L6 trans-signaling and VEGF- signaling comprising (a) an IL6/IL6 receptor alpha complex-binding extracellular vesicle (EV) protein comprising a GP130 domain 1-3 protein portion, for binding IL6/1LR. receptor alpha complex, and a chimeric vesicle localization moiety, and (b) a VEGF-binding EV protein comprising at least two VEGFR- domain fusion units, for binding VEGF, and a chimeric vesicle localization moiety, wherein each VEGFR-domain fusion unit comprises an Ig-like domain 2 of a VEGF receptor 1 (VEGFR-1) linked to an Ig-like domain 3 of VEGF receptor 2 (VEGFR-2), and wherein the chimeric vesicle localization moiety comprises: (i) a surface-and-transmembrane domain of a first vesicle localization moiety, and (ii) a cytosolic domain of a second vesicle localization moiety, the method of making said vesicle and uses thereof,[French]
Sont divulguées des vésicules extracellulaires modifiées pour inhiber la signalisation trans 1L6 et la signalisation du facteur de croissance vasculaire endothéliale (VEGF, « vascular endothelial growth factor ») comprenant (a) une protéine de vésicule extracellulaire (VE) de liaison à un complexe alpha de récepteur IL6/IL6 comprenant une partie protéine 1-3 de domaine GP130, pour lier le complexe alpha de récepteur IL6/1 LR, et une fraction de localisation de vésicule chimérique, ainsi que (b) une protéine VE de liaison à VEGF comprenant au moins deux unités de fusion de domaine VEGFR, pour lier le VEGF, ainsi qu'une fraction de localisation de vésicule chimérique, chaque unité de fusion de domaine VEGFR comprenant un domaine de type Ig 2 d'un récepteur 1 de VEGF (VEGFR-1) lié à un domaine de type Ig 3 du récepteur 2 de VEGF (VEGFR-2), la fraction de localisation de vésicule chimérique comprenant : (i) un domaine transmembranaire et de surface d'une première fraction de localisation de vésicule, ainsi que (ii) un domaine cytosolique d'une seconde fraction de localisation de vésicule, le procédé de fabrication de ladite vésicule et ses utilisations.